Squarepoint Ops LLC Acquires Shares of 63,775 Dr. Reddy's Laboratories Limited (NYSE:RDY)

Squarepoint Ops LLC bought a new position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 63,775 shares of the company's stock, valued at approximately $1,007,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in Dr. Reddy's Laboratories during the 4th quarter worth about $145,000. Blue Trust Inc. grew its stake in Dr. Reddy's Laboratories by 46.3% during the fourth quarter. Blue Trust Inc. now owns 18,210 shares of the company's stock worth $288,000 after purchasing an additional 5,763 shares during the period. Caprock Group LLC increased its holdings in Dr. Reddy's Laboratories by 280.3% in the fourth quarter. Caprock Group LLC now owns 58,563 shares of the company's stock worth $925,000 after purchasing an additional 43,165 shares in the last quarter. Waldron Private Wealth LLC lifted its stake in Dr. Reddy's Laboratories by 476.0% in the fourth quarter. Waldron Private Wealth LLC now owns 17,106 shares of the company's stock valued at $270,000 after buying an additional 14,136 shares during the period. Finally, Independence Bank of Kentucky lifted its stake in Dr. Reddy's Laboratories by 400.0% in the fourth quarter. Independence Bank of Kentucky now owns 2,775 shares of the company's stock valued at $44,000 after buying an additional 2,220 shares during the period. Institutional investors and hedge funds own 3.85% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th.

Dr. Reddy's Laboratories Stock Up 0.7%

Shares of RDY traded up $0.10 during trading hours on Wednesday, reaching $14.76. The stock had a trading volume of 2,184,616 shares, compared to its average volume of 1,487,249. The company has a market capitalization of $12.32 billion, a price-to-earnings ratio of 23.50 and a beta of 0.33. The firm has a 50-day simple moving average of $13.77 and a 200 day simple moving average of $14.02. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories Limited has a 12 month low of $12.26 and a 12 month high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.02. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The firm had revenue of $996.17 million during the quarter, compared to analysts' expectations of $83.70 billion. Equities research analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.